News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices



7/15/2014 9:37:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser® and VRx2™ platform technology, and are offered in mono-dose and multi-dose configurations. Sublingual and buccal delivery provides non-invasive, delivery of drugs, peptides, proteins and enzymes through mucosal surfaces in the oral cavity. This route avoids first pass metabolism, provides rapid systemic uptake into the body and can be self-administered by the patient. Applications include the delivery of therapeutics for pain, cardiovascular, allergy, seizure, sedation, emesis, hormones, diabetes and vaccines.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES